A randomized, double-blind placebo controlled study to evaluate the safety of STP705 administered as subcutaneous injection into healthy volunteers with either single dose escalation or multiple dose escalation

Trial Profile

A randomized, double-blind placebo controlled study to evaluate the safety of STP705 administered as subcutaneous injection into healthy volunteers with either single dose escalation or multiple dose escalation

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs STP 705 (Primary)
  • Indications Hypertrophic scars
  • Focus Adverse reactions
  • Most Recent Events

    • 03 May 2017 New trial record
    • 01 May 2017 Suzhou Sirnaomics Pharmaceuticals has received an approval from China Food and Drug Administration (CFDA) for an IND application of STP705 (Cotsiranib) for the treatment of hypertrophic scars.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top